SPOTLIGHT: Actavis receives warning letter

The FDA has issued a warning letter regarding Actavis' manufacturing facility in Little Falls, NJ. The agency has questioned its reporting of adverse medical events and raised questions regarding the marketing status of older products. No new products will be made there until the agency's concerns are satisfied. Report

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.